BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46 Suppl 5:S165-S173. [PMID: 25458776 DOI: 10.1016/j.dld.2014.10.005] [Cited by in Crossref: 163] [Cited by in F6Publishing: 151] [Article Influence: 23.3] [Reference Citation Analysis]
Number Citing Articles
1 Nagao Y, Kimura K, Kawahigashi Y, Sata M. Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals. Clin Transl Gastroenterol. 2016;7:e179. [PMID: 27388424 DOI: 10.1038/ctg.2016.37] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
2 Gragnani L, Lorini S, Marri S, Basile U, Santarlasci V, Monti M, Madia F, Petraccia L, Stasi C, Marello N, Napodano C, Annunziato F, Zignego AL. Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis. Hepatology 2021. [PMID: 33721342 DOI: 10.1002/hep.31804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Zignego AL, Gragnani L, Visentini M, Casato M. Reply. Hepatology 2017;65:1771-2. [PMID: 27943334 DOI: 10.1002/hep.28977] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
4 Basile U, Gulli F, Napodano C, Pocino K, Basile V, Marrapodi R, Colantuono S, Todi L, Marino M, Rapaccini GL, Visentini M. Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia. Biotechnol Appl Biochem 2021;68:319-29. [PMID: 32333692 DOI: 10.1002/bab.1929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Golabi P, Elsheikh E, Karrar A, Estep JM, Younossi I, Stepanova M, Gerber L, Younossi ZM. The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV). Medicine (Baltimore). 2016;95:e5066. [PMID: 27861337 DOI: 10.1097/md.0000000000005066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
6 Petta S. Hepatitis C virus and cardiovascular: A review. J Adv Res 2017;8:161-8. [PMID: 28149651 DOI: 10.1016/j.jare.2016.06.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
7 Viganò M, Colombo M. Extrahepatic Manifestations of Hepatitis C Virus. Gastroenterol Clin North Am 2015;44:775-91. [PMID: 26600219 DOI: 10.1016/j.gtc.2015.07.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
8 Hepatitis C Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Is response to anti-hepatitis C virus treatment predictive of mortality in hepatitis C virus/HIV-positive patients? AIDS 2017;31:661-8. [PMID: 28005685 DOI: 10.1097/QAD.0000000000001378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hegab DS, Sweilam MA. Cryoglobulinaemia in Egyptian Patients with Extrahepatic Cutaneous Manifestations of Chronic Hepatitis C Virus Infection. Dermatol Res Pract 2015;2015:182609. [PMID: 26839534 DOI: 10.1155/2015/182609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
10 Prud'homme S, Nevens F, Casteels I. Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals. GMS Ophthalmol Cases 2016;6:Doc05. [PMID: 27625964 DOI: 10.3205/oc000042] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Hu JH, Chang ML, Liu NJ, Yeh CT, Huang TJ. Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis. Exp Ther Med 2019;18:3568-78. [PMID: 31602234 DOI: 10.3892/etm.2019.7995] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Domont F, Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int. 2016;36:621-627. [PMID: 26763484 DOI: 10.1111/liv.13064] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
13 Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. Am Heart J. 2018;198:4-17. [PMID: 29653647 DOI: 10.1016/j.ahj.2017.10.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
14 Mohammad S, Chandio B, Soomro AA, Lakho S, Ali Z, Shaukat F. The Frequency of Cutaneous Manifestations in Hepatitis C: A Cross-sectional Study in a Tertiary Care Hospital in Pakistan. Cureus 2019;11:e6109. [PMID: 31777699 DOI: 10.7759/cureus.6109] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Stepanova M, Younossi ZM. Economic Burden of Hepatitis C Infection. Clin Liver Dis. 2017;21:579-594. [PMID: 28689595 DOI: 10.1016/j.cld.2017.03.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
16 Cacoub P, Bourliere M, Asselah T, De Ledinghen V, Mathurin P, Hézode C, Henry L, Stepanova M, Younossi ZM. French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes. Value Health 2018;21:1218-25. [PMID: 30314623 DOI: 10.1016/j.jval.2018.01.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
17 Cacoub P, Commarmond C, Sadoun D, Desbois AC. Hepatitis C Virus Infection and Rheumatic Diseases. Rheumatic Disease Clinics of North America 2017;43:123-32. [DOI: 10.1016/j.rdc.2016.09.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
18 Reau N, Vekeman F, Wu E, Bao Y, Gonzalez YS. Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy. Hepatol Commun. 2017;1:439-452. [PMID: 29404471 DOI: 10.1002/hep4.1049] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
19 Younossi Z, Blissett D, Blissett R, Henry L, Younossi Y, Beckerman R, Hunt S. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. Liver Int 2018;38:258-65. [PMID: 28719013 DOI: 10.1111/liv.13519] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
20 Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, Bagchi S. Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review. J Clin Transl Hepatol. 2017;5:343-362. [PMID: 29226101 DOI: 10.14218/jcth.2017.00021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
21 Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, Saadoun D, Desbois AC, Sebastiani M, Casato M. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15:1145-1160. [PMID: 27640316 DOI: 10.1016/j.autrev.2016.09.006] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 12.6] [Reference Citation Analysis]
22 Basile U, Gulli F, Gragnani L, Pocino K, Napodano C, Miele L, Santini SA, Marino M, Zignego AL, Rapaccini GL. Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients. Dig Liver Dis 2018;50:938-43. [PMID: 29709461 DOI: 10.1016/j.dld.2018.03.028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
23 Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10:415-423. [PMID: 26660706 DOI: 10.1007/s12072-015-9684-3] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 12.8] [Reference Citation Analysis]
24 Saleh EM, Gouda AE, Medhat AM, Ahmed HO, Shemis MA. Expression of HCV genotype-4 core antigen in prokaryotic E. coli system for diagnosis of HCV infection in Egypt. Protein Expr Purif 2021;188:105965. [PMID: 34461217 DOI: 10.1016/j.pep.2021.105965] [Reference Citation Analysis]
25 Liao TL, Chen YM, Hsieh SL, Tang KT, Chen DY, Yang YY, Liu HJ, Yang SS. Hepatitis C Virus-Induced Exosomal MicroRNAs and Toll-Like Receptor 7 Polymorphism Regulate B-Cell Activating Factor. mBio 2021;:e0276421. [PMID: 34724826 DOI: 10.1128/mBio.02764-21] [Reference Citation Analysis]
26 Kolopp-Sarda MN, Nombel A, Miossec P. Cryoglobulins Today: Detection and Immunologic Characteristics of 1,675 Positive Samples From 13,439 Patients Obtained Over Six Years. Arthritis Rheumatol 2019;71:1904-12. [PMID: 31136095 DOI: 10.1002/art.41003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
27 Romagnoli D, Marrazzo A, Ballestri S, Lonardo A, Bertolotti M. Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma. J Clin Virol 2015;69:74-7. [PMID: 26209383 DOI: 10.1016/j.jcv.2015.05.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Catanese MT, Dorner M. Advances in experimental systems to study hepatitis C virus in vitro and in vivo. Virology. 2015;479-480:221-233. [PMID: 25847726 DOI: 10.1016/j.virol.2015.03.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
29 Radovanović-Dinić B, Tešić-Rajković S, Zivkovic V, Grgov S. Clinical connection between rheumatoid arthritis and liver damage. Rheumatol Int 2018;38:715-24. [PMID: 29627896 DOI: 10.1007/s00296-018-4021-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
30 Tran TT, Mehta D, Mensa F, Park C, Bao Y, Sanchez Gonzalez Y. Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials. Infect Dis Ther 2018;7:473-84. [PMID: 30368684 DOI: 10.1007/s40121-018-0218-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Strazzulla A, Coppolino G, Di Fatta C, Giancotti F, D’Onofrio G, Postorino MC, Mazzitelli M, Mammone SV, Gentile I, Rivoli L, Palella E, Gravina T, Costa C, Pisani V, De Maria V, Barreca GS, Marascio N, Focà A, Fuiano G, Gulletta E, Torti C. Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection? World J Hepatol 2016; 8(19): 815-824 [PMID: 27429717 DOI: 10.4254/wjh.v8.i19.815] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Rutter K, Stättermayer AF, Beinhardt S, Scherzer T, Steindl-munda P, Trauner M, Ferenci P, Hofer H. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther 2015;41:521-31. [DOI: 10.1111/apt.13085] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
33 Ilyas SZ, Tabassum R, Hamed H, Rehman SU, Qadri I. Hepatitis C Virus-Associated Extrahepatic Manifestations in Lung and Heart and Antiviral Therapy-Related Cardiopulmonary Toxicity. Viral Immunol 2017;30:633-41. [PMID: 28953449 DOI: 10.1089/vim.2017.0009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
34 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index. J Gastroenterol 2016;51:380-9. [DOI: 10.1007/s00535-015-1117-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
35 Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, Antonelli A, Desbois AC, Comarmond C, Gragnani L, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P; ISG-EHCV. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16:523-541. [PMID: 28286108 DOI: 10.1016/j.autrev.2017.03.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
36 Wright N, Reimer J, Somaini L, Roncero C, Maremmani I, Simon N, Krajci P, Littlewood R, D'Agnone O, Alho H, Rolland B. Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model. Eur J Gastroenterol Hepatol 2017;29:1206-14. [PMID: 28914697 DOI: 10.1097/MEG.0000000000000962] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
37 Huang C, Chen W, Wu Y, Shen C, Hsu C, Li C, Chen M, Chang J, Chen Y, Lu C, Shi C, Chen C. Comparison of antiplatelet antibody profiles between hepatitis C virus-associated immune thrombocytopenia and primary immune thrombocytopenia. Platelets. [DOI: 10.1080/09537104.2020.1820975] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
38 Truntzer JN, Shah KN, Jenkins DR, Rubin LE. Total joint arthroplasty in patients with chronic infectious liver disease. Arthroplast Today 2016;2:69-76. [PMID: 28326402 DOI: 10.1016/j.artd.2015.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
39 Mocroft A, Lundgren JD, Rockstroh JK, Aho I, Wandeler G, Nielsen L, Edwards S, Viard JP, Lacombe K, Fätkenheuer G, Guaraldi G, Laguno M, Llibre J, Elinav H, Flamholc L, Gisinger M, Paduta D, Khromova I, Jilich D, Rozplochowski B, Oprea C, Peters L; EuroSIDA study . Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. Open Forum Infect Dis 2020;7:ofaa470. [PMID: 33409325 DOI: 10.1093/ofid/ofaa470] [Reference Citation Analysis]
40 Li Y, Wang X, Yu G, Sun H, Lv J, Chi X, Wu R, Gao X, Niu J. The association of hepatitis c virus infection status with serum glucose levels. BMC Gastroenterol. 2019;19:86. [PMID: 31195990 DOI: 10.1186/s12876-019-1003-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
41 Craxì A, Perno CF, Viganò M, Ceccherini-silberstein F, Petta S, Aghemo A, Alberti A, Andreone P, Andreoni M, Bonora S, Brunetto MR, Bruno S, Caporaso N, Chirianni A, Ciancio A, Degasperi E, Di Perri G, Fagiuoli S, Ferrari C, Gaeta GB, Pellicelli A, Puoti M, Raimondo G, Taliani G, Villa E, Zignego AL. From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease 2016;48:995-1005. [DOI: 10.1016/j.dld.2016.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
42 Badawi A, Di Giuseppe G, Arora P. Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017). PLoS One 2018;13:e0208839. [PMID: 30540839 DOI: 10.1371/journal.pone.0208839] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
43 Andreoni M, Babudieri S, Bruno S, Colombo M, Zignego AL, Di Marco V, Di Perri G, Perno CF, Puoti M, Taliani G, Villa E, Craxì A. Current and future challenges in HCV: insights from an Italian experts panel. Infection 2018;46:147-63. [PMID: 29098647 DOI: 10.1007/s15010-017-1093-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
44 Sikorska K. The iron homeostasis network and hepatitis C virus - a new challenge in the era of directly acting antivirals. Virulence. 2016;7:620-622. [PMID: 27196953 DOI: 10.1080/21505594.2016.1191739] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
45 Khan MU, Mahmoud MI, Butt AA. Hepatitis c virus and chronic kidney disease. Expert Rev Gastroenterol Hepatol 2020;14:579-90. [PMID: 32613874 DOI: 10.1080/17474124.2020.1776111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Kåberg M, Larsson SB, Jerkeman A, Nystedt A, Duberg AS, Kövamees J, Ydreborg M, Aleman S, Büsch K, Alanko Blomé M, Weiland O, Söderholm J. High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder. Scand J Gastroenterol 2020;55:574-80. [PMID: 32356496 DOI: 10.1080/00365521.2020.1754456] [Reference Citation Analysis]
48 El-Shamy A, Branch AD, Schiano TD, Gorevic PD. The Complement System and C1q in Chronic Hepatitis C Virus Infection and Mixed Cryoglobulinemia. Front Immunol 2018;9:1001. [PMID: 29910796 DOI: 10.3389/fimmu.2018.01001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
49 Angeletti A, Cantarelli C, Cravedi P. HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents. Front Med (Lausanne) 2019;6:20. [PMID: 30800660 DOI: 10.3389/fmed.2019.00020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
50 Gulli F, Santini SA, Napodano C, Bottoni P, Pocino K, Rapaccini GL, Basile U. Cryoglobulin Test and Cryoglobulinemia Hepatitis C-Virus Related. Mediterr J Hematol Infect Dis 2017;9:e2017007. [PMID: 28101312 DOI: 10.4084/MJHID.2017.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
51 de Avila L, Weinstein AA, Estep JM, Curry MP, Golabi P, Escheik C, Birerdinc A, Stepanova M, Gerber L, Younossi ZM. Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C. Liver Int 2019;39:1631-40. [PMID: 30959554 DOI: 10.1111/liv.14115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
52 Wong RJ, Saab S, Ahmed A. Extrahepatic Manifestations of Hepatitis C Virus After Liver Transplantation. Clin Liver Dis. 2017;21:595-606. [PMID: 28689596 DOI: 10.1016/j.cld.2017.03.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Li J, Gordon SC, Zhou Y, Boscarino JA, Schmidt MA, Daida YG, Rupp LB, Trudeau S, Lu M; CHeCS Investigators. Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C. Am J Gastroenterol 2021;116:576-83. [PMID: 33399360 DOI: 10.14309/ajg.0000000000001095] [Reference Citation Analysis]
54 Lee KK, Stelzle D, Bing R, Anwar M, Strachan F, Bashir S, Newby DE, Shah JS, Chung MH, Bloomfield GS, Longenecker CT, Bagchi S, Kottilil S, Blach S, Razavi H, Mills PR, Mills NL, McAllister DA, Shah ASV. Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. Lancet Gastroenterol Hepatol 2019;4:794-804. [PMID: 31377134 DOI: 10.1016/S2468-1253(19)30227-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 14.5] [Reference Citation Analysis]
55 Latini A, Orsini D, Ambrifi M, Colafigli M, Zaccarelli M, Cristaudo A. Classical Kaposi's sarcoma concurrent with ledipasvir-sofosbuvir therapy for hepatitis C infection. G Ital Dermatol Venereol 2019;154:593-4. [PMID: 29192474 DOI: 10.23736/S0392-0488.17.05788-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Fernández-Montero JV, Barreiro P, de Mendoza C, Labarga P, Soriano V. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral Hepat. 2016;23:47-52. [PMID: 26390144 DOI: 10.1111/jvh.12447] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
57 Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol 2015; 21(42): 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
58 Nakayama JY, Ho J, Cartwright E, Simpson R, Hertzberg VS. Predictors of progression through the cascade of care to a cure for hepatitis C patients using decision trees and random forests. Comput Biol Med 2021;134:104461. [PMID: 33975209 DOI: 10.1016/j.compbiomed.2021.104461] [Reference Citation Analysis]
59 Mazzaro C. Chronic hepatitis C: a systemic disease. Minerva Med 2021;112:159-61. [PMID: 33555167 DOI: 10.23736/S0026-4806.21.07410-3] [Reference Citation Analysis]
60 Mariño Z, Rodríguez-Tajes S, Bartrés C, Nácar L, Lens S, Navinés R, Cavero M, Londoño MC, Sastre L, Pocurull A, Dafieno A, Martín-Santos R, Forns X. Improvement of sexuality after hepatitis C cure with direct acting antivirals. Liver Int 2020;40:2972-7. [PMID: 33025664 DOI: 10.1111/liv.14689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Pol S, Vallet-Pichard A, Hermine O. Extrahepatic cancers and chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2018;15:283-290. [PMID: 29339810 DOI: 10.1038/nrgastro.2017.172] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
62 Kalantari H, Karimzadeh H, Kalantari S, Talebi M, Yaran M, Golpayegani J. Correlation between Vitamin D3 level and extrahepatic manifestation in chronic hepatitis type-C virus patients. J Res Med Sci 2018;23:22. [PMID: 29692819 DOI: 10.4103/jrms.JRMS_366_17] [Reference Citation Analysis]
63 Soriano V, Barreiro P, de Mendoza C. Hypoglycemia in a diabetic patient during hepatitis C therapy: Hepatology, Vol. XX, No. X, 2015 Correspondence. Hepatology 2016;63:2065-6. [DOI: 10.1002/hep.28137] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
64 Cacoub P, Comarmond C. Considering hepatitis C virus infection as a systemic disease. Semin Dial 2019;32:99-107. [PMID: 30549107 DOI: 10.1111/sdi.12758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Gulli F, Basile U, Gragnani L, Fognani E, Napodano C, Colacicco L, Miele L, De Matthaeis N, Cattani P, Zignego AL, Rapaccini GL. Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders. Digestive and Liver Disease 2016;48:927-33. [DOI: 10.1016/j.dld.2016.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
66 Rajasekaran A, Franco RA, Overton ET, McGuire BM, Towns GC, Locke JE, Sawinski DL, Bell EK. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep 2021;6:1788-98. [PMID: 34307975 DOI: 10.1016/j.ekir.2021.04.015] [Reference Citation Analysis]
67 Badawi A, Di Giuseppe G, Gupta A, Poirier A, Arora P. Bayesian network modelling study to identify factors influencing the risk of cardiovascular disease in Canadian adults with hepatitis C virus infection. BMJ Open 2020;10:e035867. [PMID: 32371519 DOI: 10.1136/bmjopen-2019-035867] [Reference Citation Analysis]
68 Sayiner M, Golabi P, Farhat F, Younossi ZM. Dermatologic Manifestations of Chronic Hepatitis C Infection. Clinics in Liver Disease 2017;21:555-64. [DOI: 10.1016/j.cld.2017.03.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
69 Dedania B, Wu GY. Dermatologic Extrahepatic Manifestations of Hepatitis C. J Clin Transl Hepatol. 2015;3:127-133. [PMID: 26357639 DOI: 10.14218/jcth.2015.00010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
70 Rey D, Muret P, Piroth L. Optimum combination therapy regimens for HIV/HCV infection. Expert Rev Anti Infect Ther 2016;14:299-309. [PMID: 26822803 DOI: 10.1586/14787210.2016.1147952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
71 Gantumur G, Batsaikhan B, Huang CI, Yeh ML, Huang CF, Lin YH, Lin TC, Liang PC, Liu TW, Lee JJ, Lin YC, Lin IL, Huang JF, Chuang WL, Yu ML, Tu HP, Dai CY. The association between hepatitis C virus infection and renal function. J Chin Med Assoc 2021;84:757-65. [PMID: 34074934 DOI: 10.1097/JCMA.0000000000000561] [Reference Citation Analysis]
72 Yeboah-Korang A, Beig MI, Khan MQ, Goldstein JL, Macapinlac DM, Maurer D, Sonnenberg A, Fimmel CJ. Hepatitis C Screening in Commercially Insured U.S. Birth-cohort Patients: Factors Associated with Testing and Effect of an EMR-based Screening Alert. J Transl Int Med 2018;6:82-9. [PMID: 29984203 DOI: 10.2478/jtim-2018-0012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
73 Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Téllez MJ, Quereda C, Sanz J, Barros C, Tural C, Santos I, Pulido F, Guardiola JM, Rubio R, Ortega E, Montes ML, Jusdado JJ, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2017;66:344-56. [PMID: 28109003 DOI: 10.1002/hep.29071] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
74 Golabi P, Sayiner M, Bush H, Gerber LH, Younossi ZM. Patient-Reported Outcomes and Fatigue in Patients with Chronic Hepatitis C Infection. Clin Liver Dis. 2017;21:565-578. [PMID: 28689594 DOI: 10.1016/j.cld.2017.03.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
75 Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14:122-132. [PMID: 27924080 DOI: 10.1038/nrgastro.2016.176] [Cited by in Crossref: 196] [Cited by in F6Publishing: 193] [Article Influence: 39.2] [Reference Citation Analysis]
76 Fernandes B, Dias E, Mascarenhas-Saraiva M, Bernardes M, Costa L, Cardoso H, Macedo G. Rheumatologic manifestations of hepatic diseases. Ann Gastroenterol 2019;32:352-60. [PMID: 31263357 DOI: 10.20524/aog.2019.0386] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Palazzi C, D’Amico E, D’Angelo S, Gilio M, Olivieri I. Rheumatic manifestations of hepatitis C virus chronic infection: Indications for a correct diagnosis. World J Gastroenterol 2016; 22(4): 1405-1410 [PMID: 26819509 DOI: 10.3748/wjg.v22.i4.1405] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
78 Basile U, Gulli F, Gragnani L, Fognani E, Napodano C, Pocino K, Zignego AL, Rapaccini GL. IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection. Dig Liver Dis 2017;49:1233-9. [PMID: 28688880 DOI: 10.1016/j.dld.2017.06.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
79 Rostaing L, Alric L, Kamar N. Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. Transpl Int 2016;29:1257-65. [DOI: 10.1111/tri.12870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
80 Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society? Liver Int 2017;37:662-8. [PMID: 27804195 DOI: 10.1111/liv.13298] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
81 Filho HRM, Bierrenbach ALS, Capuani MLD, Mendrone A Jr, Benzaken AS, Machado SM, Saivish MV, Sabino EC, Witkin SS, Mendes-Corrêa MC. Impact on mortality of being seropositive for hepatitis C virus antibodies among blood donors in Brazil: A twenty-year study. PLoS One 2019;14:e0226566. [PMID: 31856222 DOI: 10.1371/journal.pone.0226566] [Reference Citation Analysis]
82 Urraro T, Gragnani L, Piluso A, Fabbrizzi A, Monti M, Fognani E, Boldrini B, Ranieri J, Zignego AL. Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. Case Reports Immunol. 2015;2015:816424. [PMID: 25815218 DOI: 10.1155/2015/816424] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
83 Torres HA, Mahale P. Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization. Liver Int. 2015;35:1661-1664. [PMID: 25779000 DOI: 10.1111/liv.12825] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
84 Cacoub P. Hepatitis C Virus Infection, a New Modifiable Cardiovascular Risk Factor. Gastroenterology 2019;156:862-4. [DOI: 10.1053/j.gastro.2019.02.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
85 Dejman A, Ladino MA, Roth D. Treatment and management options for the hepatitis C virus infected kidney transplant candidate. Hemodial Int 2018;22 Suppl 1:S36-44. [PMID: 29694726 DOI: 10.1111/hdi.12646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
86 Li X, Gao Y, Xu H, Hou J, Gao P. Diabetes mellitus is a significant risk factor for the development of liver cirrhosis in chronic hepatitis C patients. Sci Rep. 2017;7:9087. [PMID: 28831144 DOI: 10.1038/s41598-017-09825-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
87 de Camargo AR, Tenório JR, Martins F, Grando LJ, Corrêa EBD, Trierveiler M, Ortega KL. Subset of CD8+ and FOXP3 + T cells in lichen planus associated with chronic hepatitis C infection. Oral Dis 2019;25:1100-6. [PMID: 30801844 DOI: 10.1111/odi.13069] [Reference Citation Analysis]
88 Halfon P, Ansaldi C, Penaranda G, Chiche L, Dukan P, Stavris C, Plauzolles A, Retornaz F, Bourliere M. Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results. PLoS One 2021;16:e0254939. [PMID: 34293022 DOI: 10.1371/journal.pone.0254939] [Reference Citation Analysis]
89 Owusu Sekyere S, Suneetha PV, Hardtke S, Falk CS, Hengst J, Manns MP, Cornberg M, Wedemeyer H, Schlaphoff V. Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C. Front Immunol 2015;6:270. [PMID: 26113847 DOI: 10.3389/fimmu.2015.00270] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
90 Ivanenkov YA, Aladinskiy VA, Bushkov NA, Ayginin AA, Majouga AG, Ivachtchenko AV. Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015). Expert Opin Ther Pat 2017;27:401-14. [PMID: 27967269 DOI: 10.1080/13543776.2017.1272573] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
91 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. J Gastroenterol Hepatol. 2017;32:687-694. [PMID: 27577675 DOI: 10.1111/jgh.13589] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
92 Mazzaro C, Dal Maso L, Mauro E, Visentini M, Tonizzo M, Gattei V, Andreone P, Pozzato G. Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy. Autoimmunity Reviews 2020;19:102589. [DOI: 10.1016/j.autrev.2020.102589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
93 Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. Hepatology. 2018;68:827-838. [PMID: 29377196 DOI: 10.1002/hep.29811] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 29.7] [Reference Citation Analysis]
94 Cacoub P, Desbois AC, Isnard-Bagnis C, Rocatello D, Ferri C. Hepatitis C virus infection and chronic kidney disease: Time for reappraisal. J Hepatol. 2016;65:S82-S94. [PMID: 27641990 DOI: 10.1016/j.jhep.2016.06.011] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 19.3] [Reference Citation Analysis]
95 Kolopp-Sarda MN, Miossec P. Contribution of Hepatitis C Infection to a Large Cohort of Cryoglobulin-Positive Patients: Detection and Characteristics. Front Immunol 2020;11:1183. [PMID: 32695098 DOI: 10.3389/fimmu.2020.01183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Abrantes J, Torres DS, Brandão-Mello CE. The Many Difficulties and Subtleties in the Cognitive Assessment of Chronic Hepatitis C Infection. Int J Hepatol 2020;2020:9675235. [PMID: 32257447 DOI: 10.1155/2020/9675235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
97 Desbois AC, Comarmond C, Saadoun D, Cacoub P. Cryoglobulinemia vasculitis: how to handle. Curr Opin Rheumatol. 2017;29:343-347. [PMID: 28368978 DOI: 10.1097/bor.0000000000000390] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
98 Adinolfi LE, Nevola R, Rinaldi L, Romano C, Giordano M. Chronic Hepatitis C Virus Infection and Depression. Clin Liver Dis 2017;21:517-34. [PMID: 28689590 DOI: 10.1016/j.cld.2017.03.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
99 Henson JB, Sise ME. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial 2019;32:108-18. [PMID: 30496620 DOI: 10.1111/sdi.12759] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
100 Konstantinides P, Alexopoulou A, Hadziyannis E, Kanellopoulou T, Dourakis SP. Interleukin-17A and B-cell activating factor in chronic hepatitis C patients with or without asymptomatic mixed cryoglobulinemia: effects of antiviral treatment and correlations with vitamin D. Ann Gastroenterol 2018;31:705-11. [PMID: 30386121 DOI: 10.20524/aog.2018.0310] [Reference Citation Analysis]
101 Mazzaro C, Dal Maso L, Urraro T, Mauro E, Castelnovo L, Casarin P, Monti G, Gattei V, Zignego AL, Pozzato G. Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC. Dig Liver Dis. 2016;48:780-784. [PMID: 27106525 DOI: 10.1016/j.dld.2016.03.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
102 Mazzaro C, Dal Maso L, Visentini M, Ermacora A, Andreone P, Gattei V, Pozzato G. Hepatitis C virus‐associated indolent B‐cell lymphomas: A review on the role of the new direct antiviral agents therapy. Hematological Oncology 2021;39:439-47. [DOI: 10.1002/hon.2862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Isnard Bagnis C, Cacoub P. Hepatitis C Therapy in Renal Patients: Who, How, When? Infect Dis Ther 2016;5:313-27. [PMID: 27388502 DOI: 10.1007/s40121-016-0116-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
104 Misselwitz B, Epprecht J, Mertens J, Biedermann L, Scharl M, Haralambieva E, Lutterotti A, Weber KP, Müllhaupt B, Chaloupka K. Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection. Case Rep Gastroenterol 2016;10:108-14. [PMID: 27403111 DOI: 10.1159/000444011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
105 Economides MP, Mahale P, Turturro F, Hosry J, Samaniego F, Granwehr BP, Torres HA. Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy. Leuk Lymphoma 2017;58:485-8. [PMID: 27348218 DOI: 10.1080/10428194.2016.1196817] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
106 Sugiura A, Wada S, Mori H, Kimura T, Matsuda Y, Tanaka N, Tanaka E, Kiyosawa K. Successful Treatment for Chronic Hepatitis C-Autoimmune Hepatitis Overlap Syndrome due to Daclatasvir and Asunaprevir. Case Rep Gastroenterol 2017;11:305-11. [PMID: 28626376 DOI: 10.1159/000475752] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
107 Mazzaro C, Mauro E, Ermacora A, Doretto P, Fumagalli S, Tonizzo M, Toffolutti F, Gattei V. Hepatitis C virus- related cryoglobulinemic vasculitis. Minerva Med. 2020;. [PMID: 33198444 DOI: 10.23736/s0026-4806.20.07120-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Ponziani FR, Miele L, Tortora A, Furnari M, Bodini G, Pompili M, Gasbarrini A, Giannini EG. Treatment of early stage chronic hepatitis C virus infection. Expert Rev Clin Pharmacol 2018;11:519-24. [PMID: 29498556 DOI: 10.1080/17512433.2018.1447923] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
109 Chlilek A, Roger C, Muller L, Carles MJ, Stephan R, Laureillard D, Lavigne JP, Lefrant JY, Sotto A. Severe Guillain-Barré syndrome associated with chronic active hepatitis C and mixed cryoglobulinemia: a case report. BMC Infect Dis 2019;19:636. [PMID: 31315560 DOI: 10.1186/s12879-019-4278-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Ignatova TM, Kozlovskaya LV, Gordovskaya NB, Chernova OA, Milovanova SY, Novikov PI, Nekrasova TP, Beketova TV, Mukhin NA. [Hepatitis C virus-associated cryoglobulinemic vasculitis: A 20-year experience with treatment]. Ter Arkh 2017;89:46-52. [PMID: 28631698 DOI: 10.17116/terarkh201789546-52] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
111 Visentini M, Fiorilli M, Casato M. From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals? Expert Rev Hematol 2017;10:719-27. [PMID: 28675071 DOI: 10.1080/17474086.2017.1349607] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
112 Basile U, Napodano C, Pocino K, Gulli F, Santini SA, Todi L, Marino M, Rapaccini GL. Serological profile of asymptomatic HCV positive patients with low level of cryoglobulins. Biofactors 2019;45:318-25. [PMID: 30561820 DOI: 10.1002/biof.1485] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
113 Kim SM, Song IH. Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. Korean J Intern Med 2018;33:670-8. [PMID: 29961309 DOI: 10.3904/kjim.2018.202] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
114 Andreone P, Di Marco V, Gaeta GB, Fagiuoli S, Vukotic R, Craxì A. Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. Dig Liver Dis 2019;51:915-21. [PMID: 31031174 DOI: 10.1016/j.dld.2019.03.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
115 Soriano V, Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients: . Current Opinion in HIV and AIDS 2015;10:309-15. [DOI: 10.1097/coh.0000000000000175] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
116 Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L, Perez M, Ceccotti G, Colantuono S, Mitrevski M, Stasi C, Del Padre M, Monti M, Gianni E, Pulsoni A, Fiorilli M, Casato M, Zignego AL. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64:1473-1482. [PMID: 27483451 DOI: 10.1002/hep.28753] [Cited by in Crossref: 129] [Cited by in F6Publishing: 114] [Article Influence: 25.8] [Reference Citation Analysis]
117 Indolfi G, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N, Czubkowski P, Gupte G, Mozer-Glassberg Y, van der Woerd W, Smets F, Verkade HJ, Fischler B. Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:505-515. [PMID: 29287014 DOI: 10.1097/mpg.0000000000001872] [Cited by in Crossref: 58] [Cited by in F6Publishing: 20] [Article Influence: 29.0] [Reference Citation Analysis]
118 Scudiero F, Valenti R, Marcucci R, Sanna GD, Gori AM, Migliorini A, Vitale R, Giusti B, De Vito E, Corda G, Paniccia R, Zirolia D, Canonico ME, Parodi G. Platelet Reactivity in Hepatitis C Virus-Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome. J Am Heart Assoc 2020;9:e016441. [PMID: 32885738 DOI: 10.1161/JAHA.120.016441] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
119 Desbois AC, Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol 2017; 23(9): 1697-1711 [PMID: 28321170 DOI: 10.3748/wjg.v23.i9.1697] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 40] [Article Influence: 11.8] [Reference Citation Analysis]
120 Weinstein AA, Estep JM, de Avila L, Curry M, Golabi P, Escheik C, Birerdinc A, Stepanova M, Price JK, Gerber L, Younossi ZM. Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study. J Neuroimmunol 2019;335:577022. [PMID: 31445380 DOI: 10.1016/j.jneuroim.2019.577022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
121 Carvalho JR, Velosa J, Serejo F. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens. Scand J Gastroenterol. 2018;53:857-863. [PMID: 29779403 DOI: 10.1080/00365521.2018.1473486] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
122 Lawitz E, Flisiak R, Abunimeh M, Sise ME, Park JY, Kaskas M, Bruchfeld A, Wörns MA, Aglitti A, Zamor PJ, Xue Z, Schnell G, Jalundhwala YJ, Porcalla A, Mensa FJ, Persico M. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int 2020;40:1032-41. [PMID: 31821716 DOI: 10.1111/liv.14320] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
123 Priora M, Realmuto C, Parisi S, Ditto MC, Borrelli R, Peroni CL, Laganà A, Fusaro E. Rheumatologic manifestations of hepatitis C in the era of direct-acting antiviral agents. Minerva Gastroenterol Dietol 2020;66:280-9. [PMID: 32218427 DOI: 10.23736/S1121-421X.20.02680-X] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Cacoub P, Vautier M, Desbois AC, Saadoun D, Younossi Z. Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. Aliment Pharmacol Ther. 2018;47:123-128. [PMID: 29044584 DOI: 10.1111/apt.14382] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
125 Chen K, Lu P, Song R, Zhang J, Tao R, Wang Z, Zhang W, Gu M. Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study. Medicine (Baltimore) 2017;96:e7568. [PMID: 28746204 DOI: 10.1097/MD.0000000000007568] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
126 Kiberd BA, Doucette K, Vinson AJ, Tennankore KK. Hepatitis C virus-infected kidney waitlist patients: Treat now or treat later? Am J Transplant 2018;18:2443-50. [PMID: 29687948 DOI: 10.1111/ajt.14891] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
127 Lin MS, Chen PH, Wang PC, Lin HS, Huang TJ, Chang ST, Chiu WN, Chen MY. Association between hepatitis C virus infection and osteoporotic fracture risk among postmenopausal women: a cross-sectional investigation in Taiwan. BMJ Open 2019;9:e021990. [PMID: 30782676 DOI: 10.1136/bmjopen-2018-021990] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
128 da Mata GF, Fernandes DE, Luciano EP, Sales GTM, Riguetti MTP, Kirsztajn GM. Inflammation and kidney involvement in human viral diseases caused by SARS-CoV-2, HIV, HCV and HBV. J Venom Anim Toxins Incl Trop Dis 2021;27:e20200154. [PMID: 34381495 DOI: 10.1590/1678-9199-JVATITD-2020-0154] [Reference Citation Analysis]
129 Collister M, Ellison C, Li Q, Minuk GY, Rempel JD, Kung SK. The Influence of Hepatitis C Viral Loads on Natural Killer Cell Function. Gastroenterology Res 2019;12:8-15. [PMID: 30834029 DOI: 10.14740/gr1081w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
130 Ladino M, Pedraza F, Roth D. Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. World J Hepatol 2017; 9(19): 833-839 [PMID: 28740594 DOI: 10.4254/wjh.v9.i19.833] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
131 Kong F, Zhang W, Feng B, Zhang H, Rao H, Wang J, Cong X, Wei L. Abnormal CD4 + T helper (Th) 1 cells and activated memory B cells are associated with type III asymptomatic mixed cryoglobulinemia in HCV infection. Virol J. 2015;12:100. [PMID: 26129991 DOI: 10.1186/s12985-015-0324-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
132 Mehta DA, Cohen E, Charafeddine M, Cohen DE, Bao Y, Sanchez Gonzalez Y, Tran TT. Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R+ Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials. Infect Dis Ther. 2017;6:515-529. [PMID: 28939957 DOI: 10.1007/s40121-017-0171-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
133 Alsebaey A, Elhelbawy M, Abdel-Razek W, Hashim M, Elshenawy H, Waked I. HCV treatment with direct acting antivirals improves the insulin sensitivity. Expert Rev Anti Infect Ther. 2019;17:749-754. [PMID: 31393188 DOI: 10.1080/14787210.2019.1653184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
134 Cacoub P, Comarmond C, Desbois AC, Saadoun D. Rheumatologic Manifestations of Hepatitis C Virus Infection. Clinics in Liver Disease 2017;21:455-64. [DOI: 10.1016/j.cld.2017.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
135 Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Review of Gastroenterology & Hepatology 2016;10:1227-34. [DOI: 10.1080/17474124.2016.1234375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
136 Iqbal T, Mahale P, Turturro F, Kyvernitakis A, Torres HA. Prevalence and association of hepatitis C virus infection with different types of lymphoma. Int J Cancer 2016;138:1035-7. [PMID: 26356141 DOI: 10.1002/ijc.29845] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
137 Younossi ZM, Henry L, P. Ong J, Tanaka A, Eguchi Y, Mizokami M, Lim Y, Dan YY, Yu M, Stepanova M. Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. Aliment Pharmacol Ther 2019;49:644-53. [DOI: 10.1111/apt.15131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
138 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Reference Citation Analysis]
139 Gragnani L, Fognani E, De Re V, Libra M, Garozzo A, Caini P, Cerretelli G, Giovannelli A, Lorini S, Monti M, Bagnoli S, Piaceri I, Zignego AL. Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases. Oncotarget 2017;8:71528-35. [PMID: 29069725 DOI: 10.18632/oncotarget.17655] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
140 Tang L, Marcell L, Kottilil S. Systemic manifestations of hepatitis C infection. Infect Agent Cancer. 2016;11:29. [PMID: 27222662 DOI: 10.1186/s13027-016-0076-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
141 Armand M, Besson C, Hermine O, Davi F. Hepatitis C virus - Associated marginal zone lymphoma. Best Pract Res Clin Haematol 2017;30:41-9. [PMID: 28288715 DOI: 10.1016/j.beha.2017.02.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
142 Söderholm J, Millbourn C, Büsch K, Kövamees J, Schvarcz R, Lindahl K, Bruchfeld A. Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. Journal of Hepatology 2018;68:904-11. [DOI: 10.1016/j.jhep.2017.12.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
143 Thorne C, Indolfi G, Turkova A, Giaquinto C, Nastouli E. Treating hepatitis C virus in children: time for a new paradigm. J Virus Erad. 2015;1:203-205. [PMID: 27482412 DOI: 10.1016/s2055-6640(20)30500-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
144 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016;17:355. [PMID: 27005620 DOI: 10.3390/ijms17030355] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
145 Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver Illness and Psoriatic Patients. Biomed Res Int 2018;2018:3140983. [PMID: 29546055 DOI: 10.1155/2018/3140983] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
146 Xie Q, Xuan JW, Tang H, Ye XG, Xu P, Lee IH, Hu SL. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol 2019; 11(5): 421-441 [PMID: 31183003 DOI: 10.4254/wjh.v11.i5.421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
147 Mapoure NY, Budzi MN, Eloumou SAFB, Malongue A, Okalla C, Luma HN. Neurological manifestations in chronic hepatitis C patients receiving care in a reference hospital in sub-Saharan Africa: A cross-sectional study. PLoS One. 2018;13:e0192406. [PMID: 29513678 DOI: 10.1371/journal.pone.0192406] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
148 Cornella SL, Stine JG, Kelly V, Caldwell SH, Shah NL. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med. 2015;127:413-417. [PMID: 25746436 DOI: 10.1080/00325481.2015.1021660] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 8.7] [Reference Citation Analysis]
149 Nuño Solinís R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther 2016;5:491-508. [PMID: 27783223 DOI: 10.1007/s40121-016-0134-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
150 Cacoub P, Comarmond C. New insights into HCV-related rheumatologic disorders: A review. J Adv Res 2017;8:89-97. [PMID: 28149645 DOI: 10.1016/j.jare.2016.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
151 Lledó G, Benítez-Gutiérrez L, Arias A, Requena S, Cuervas-Mons V, de Mendoza C. Benefits of hepatitis C cure with antivirals: why test and treat? Future Microbiol 2019;14:425-35. [PMID: 30900911 DOI: 10.2217/fmb-2019-0041] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]